Given considerably lower toxicity and relative ease of administering oral therapies in comparison with other systemic treatments, pET can be considered an effective approach in LMICs [1], particularly in a country like Ethiopia where radiation treatment is limited and more than 65% of breast cancer tumours are ER positive [35]. The gene discussed is ESR1; the disease is breast carcinoma.